Industry analysts say health systems are not fully prepared for the next wave of GLP-1-based care that extends beyond diabetes and obesity into broader cardiometabolic and liver indications. The core issue is operational: regulators have expanded use cases, but affordability, appropriate long-term prescribing, and payer coverage remain unresolved. The outlook highlights the need for care models that can support chronic treatment over years, not months, while primary care systems absorb complex metabolic care without sufficient infrastructure. Analysts also point to upcoming drug class diversification—including triple agonists and oral formulations—that will multiply evidence and patient-support demands. For biotech decision-makers, the takeaway is that competitive advantage may depend as much on evidence strategy and delivery partnerships as on trial results.